Pacira BioSciences Reports Full-Year 2019 Preliminary Revenue of $421.0 MillionGlobeNewsWire • 01/09/20
EXPAREL Achieves Primary and Key Secondary Endpoints in Phase 4 CHOICE Study in Cesarean Section PatientsGlobeNewsWire • 01/07/20
Pacira BioSciences Announces Positive Results from Phase 3 PLAY Study of EXPAREL® in Pediatric PatientsGlobeNewsWire • 12/17/19
Pacira (PCRX) Up 7.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/07/19
Pacira BioSciences to Present at the Jefferies 2019 London Healthcare ConferenceGlobeNewsWire • 11/13/19
Pacira BioSciences, Inc.'s (PCRX) CEO Dave Stack on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/07/19
Pacira (PCRX) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 10/31/19
Pacira (PCRX) Down 15.3% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/07/19
Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/08/19
Pacira Biosciences Inc (PCRX) CEO and Chairman David M Stack Sold $562,371 of SharesGuruFocus • 07/10/19